Literature DB >> 8282069

Expression of neurotrophins by midbrain dopaminergic neurons.

K B Seroogy1, C M Gall.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8282069     DOI： 10.1006/exnr.1993.1182

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  16 in total

Review 1.  Neurotrophic mechanisms in drug addiction.

Authors:  Carlos A Bolaños; Eric J Nestler
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

2.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons.

Authors:  L Sklair-Tavron; W X Shi; S B Lane; H W Harris; B S Bunney; E J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 4.  Understanding opioid reward.

Authors:  Howard L Fields; Elyssa B Margolis
Journal:  Trends Neurosci       Date:  2015-01-29       Impact factor: 13.837

5.  Evidence that brain-derived neurotrophic factor from presynaptic nerve terminals regulates the phenotype of calbindin-containing neurons in the lateral septum.

Authors:  J P Fawcett; M A Alonso-Vanegas; S J Morris; F D Miller; A F Sadikot; R A Murphy
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

6.  Developmental expression of neurotrophins and their receptors in postnatal rat ventral midbrain.

Authors:  Suzanne Numan; Christine M Gall; Kim B Seroogy
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 7.  Establishing causality for dopamine in neural function and behavior with optogenetics.

Authors:  Elizabeth E Steinberg; Patricia H Janak
Journal:  Brain Res       Date:  2012-09-29       Impact factor: 3.252

8.  TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin.

Authors:  T Sobreviela; D O Clary; L F Reichardt; M M Brandabur; J H Kordower; E J Mufson
Journal:  J Comp Neurol       Date:  1994-12-22       Impact factor: 3.215

9.  Differential regulation of neurotrophin and trk receptor mRNAs in catecholaminergic nuclei during chronic opiate treatment and withdrawal.

Authors:  S Numan; S B Lane-Ladd; L Zhang; K H Lundgren; D S Russell; K B Seroogy; E J Nestler
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

Review 10.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.